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Activating RNAs associate with Mediator to enhance
chromatin architecture and transcription
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Recent advances in genomic research have revealed the existence of
a large number of transcripts devoid of protein-coding potential in
multiple organisms1–8. Although the functional role for long non-
coding RNAs (lncRNAs) has been best defined in epigenetic phe-
nomena such as X-chromosome inactivation and imprinting,
different classes of lncRNAs may have varied biological func-
tions8–13. We and others have identified a class of lncRNAs, termed
ncRNA-activating (ncRNA-a), that function to activate their
neighbouring genes using a cis-mediated mechanism5,14–16. To
define the precise mode by which such enhancer-like RNAs func-
tion, we depleted factors with known roles in transcriptional acti-
vation and assessed their role in RNA-dependent activation. Here
we report that depletion of the components of the co-activator
complex, Mediator, specifically and potently diminished the
ncRNA-induced activation of transcription in a heterologous
reporter assay using human HEK293 cells. In vivo, Mediator is
recruited to ncRNA-a target genes and regulates their expression.
We show that ncRNA-a interact withMediator to regulate its chro-
matin localization and kinase activity towards histone H3 serine
10. The Mediator complex harbouring disease-causing MED12
mutations17,18 displays diminished ability to associate with acti-
vating ncRNAs. Chromosome conformation capture confirmed
the presence of DNA looping between the ncRNA-a loci and its
targets. Importantly, depletion of Mediator subunits or ncRNA-a
reduced the chromatin looping between the two loci. Our results
identify the human Mediator complex as the transducer of acti-
vating ncRNAs and highlight the importance of Mediator and
activating ncRNA association in human disease.
To define the transcriptional complex(es) that orchestrate the
responsiveness of activating lncRNAs, we used HEK293 stable cell
lines expressing the heterologous TK promoter driving luciferase
expression fused to ncRNA-a7 (also called LINC00651) controlled by
its own natural promoter and depleted factors known to be involved in
transcriptional activation and enhancer function. We also developed
stable lines expressing control reporters, in which a DNA fragment
devoid of any transcriptional activitywas substituted for the ncRNA-a7
genomic region (Fig. 1a). Importantly, depletion of ncRNA-a7 using
two different short interfering RNAs (siRNAs) specifically decreased
the transcription of the reporter construct containing ncRNA-a7
(Fig. 1b). Next, we depleted factors known to be involved in transcrip-
tional activation (Supplementary Fig. 1a) and examined the respon-
siveness of cell lines harbouring the constructs expressing ncRNA-a7
or control constructs devoid of lncRNAs. Interestingly, only depletion
of the Mediator subunit MED12 displayed a differential effect on the
transcription of the reporter construct containing ncRNA-a7 (Fig. 1c).
Depletion of other factors was either ineffective in changing transcrip-
tional output (CDK9, CCNT1, NIPBL orWDR5) or reduced the tran-
scriptional levels for both constructs (GTF2B, p300, SMC1) (Fig. 1c).
Mediator contains a complex andmodular subunit composition19,20.
We depleted different components of Mediator corresponding to the
head, middle or the tail modules and assessed their effect on the
responsiveness of the cell lines harbouring the constructs driven by
ncRNA-a7 or the control construct. Overall, depletion of other sub-
units of the Mediator complex also reduced the ncRNA-a7-induced
activation, although therewas also a small reduction in transcription of
the control plasmid with depletion of some of the subunits (Fig. 1d and
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Figure 1 | Mediator confers the ncRNA-a-dependent activation of a
heterologous reporter. a, Schematic representation of genomic control insert
(top) or ncRNA-a7 insert (bottom) in luciferase reporter vector driven by a TK
promoter. b, Depletion of ncRNA-a7 reduces the luciferase activity in the
ncRNA-a7 luciferase reporter cell lines. c, Depletion of the transcription factors
or enhancers in the control or ncRNA-a7 reporter cell lines. The red bar
indicates reduced transcription using siRNA againstMED12, comparable with
siRNA against ncRNA-a7. d, Depletion of different Mediator subunits (head,
middle and tail) using the ncRNA-a7 reporter cell lines. e, Depletion of the
Mediator subunits in ncRNA-a1 or ncRNA-a3 luciferase reporter cell lines. All
data shown are mean6 s.e.m. of three independent experiments. **P, 0.01,
***P, 0.001 by two-tailed Student’s t-test. F/R, firefly luciferase/Renilla
luciferase.
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Supplementary Fig. 1b). Similar to its effects on ncRNA-a7, depletion
of the Mediator subunits decreased the RNA-induced activation of
two other ncRNA-a, which were previously shown to regulate ECM1
and TAL1 genes (Fig. 1e). Taken together, these results identify the
Mediator complex as a transducer of ncRNA-a function.
We next depleted the Mediator subunits and assessed their effect on
ncRNA-a targets in vivo. We previously found that ncRNA-a7 and
ncRNA-a3 regulate SNAI1 and TAL1 genes, respectively5. Moreover,
using gene expression arrays, we had observed a profound decrease in
AURKA transcription when ncRNA-a7 was depleted5. We confirmed
these results by depleting ncRNA-a7 and ncRNA-a3, which led to a
decrease in SNAI1, AURKA and TAL1 transcript levels using real-time
PCR(Fig. 2a, b).Wenextdepleted twodifferent subunits of theMediator
complex, MED1 and MED12, and assessed the SNAI1, AURKA and
TAL1 transcript levels (Supplementary Fig. 1b). Importantly, depletion
of Mediator subunits decreased transcription of all three targets similar
to that shown with depletion of ncRNA-a (Fig. 2a, b, the affected genes
are depicted by a black bar). Interestingly, depletion of Mediator sub-
units did not affect the transcript levels of genes that are not regulated by
ncRNA-a (UBE2V1, CSTF, STIL, depicted by a white bar in Fig. 2a, b).
However, whereas ncRNA-a7 transcription was not affected after
Mediator depletion, there was a decrease in ncRNA-a3 levels (Fig. 2a, b).
To ensure that such transcriptional effects after Mediator depletion
were direct, we performed chromatin immunoprecipitation (ChIP)
using antibodies against the MED12 and MED1 subunits of Media-
tor. This analysis revealed that the Mediator complex occupied the
promoters of ncRNA-a3, ncRNA-a7 and their targets (Fig. 2c, d).
Moreover, we foundRNApolymerase II (RNAPII) at these promoters,
consistent with Mediator occupancy (Fig. 2c, d). Importantly, deple-
tion of ncRNA-a7 or ncRNA-a3 decreased the occupancy of Mediator
and RNAPII at their target genes without affecting the occupancy
at genes not regulated by ncRNA-a (Fig. 2c, d). These results indicate
that the Mediator complex occupies the promoters of genes regulated
by ncRNA-a, and depletion of ncRNA decreases the occupancy of
Mediator at these sites.
The Mediator complex, via its CDK8 module, displays kinase acti-
vity towards histone H3 serine 10 (H3S10), a histone modification
with strong ties to transcriptional activation21,22. We next assessed
whether ncRNA-a regulate Mediator kinase activity towards histone
H3. Addition of ncRNA-a7 or ncRNA-a3 led to a significant stimu-
lation of the Mediator kinase activity towards histone H3, whereas the
addition of primary let7b ncRNA or ncRNA HOTAIR had no effect
(Fig. 2e, f and Supplementary Fig. 2a). Such stimulation of Mediator
kinase activity by ncRNA-a was specific towards histone H3 as the
substrate. We did not observe any stimulation when GST–CTD (cor-
responding to the C-terminal domain of RPB1) or cyclinHwas used as
substrates (Supplementary Fig. 2b, c). Moreover, consistent with a role
for ncRNA-a in stimulation of histone H3 phosphorylation, depletion
of ncRNA-a7 or ncRNA-a3 led to a specific decrease inH3S10 levels at
SNAI1, AURKA and TAL1 (Supplementary Fig. 2d and e).
We next asked whether ncRNA-a could associate with theMediator
complex. We isolated Mediator using stable cell lines expressing Flag-
epitope-tagged MED12 and examined its interaction with in-vitro-
transcribed ncRNA-a7. An eluate from a stable Flag–GFP cell line
was used as a control (Fig. 3a). Whereas the control primary let7
transcript (pri-let7) or the ncRNA HOTAIR (a 429-nucleotide RNA
with a similar base composition as ncRNA-a7) did not specifically
interact with the Mediator complex, we detected a robust and specific
association between ncRNA-a7 and the Mediator complex (Fig. 3a).
Notably,Mediator also associatedwith ncRNA-a1 andncRNA-a3, two
other ncRNA-a that were shown to activate transcription of their
neighbouring genes5 (Fig. 3b).
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Figure 2 | Functional association of Mediator and activating ncRNAs.
a, Knockdown of ncRNA-a7 or Mediator subunits decreases expression of
SNAI1 and AURKA. Depletion of ncRNA-a7 diminished SNAI1 and AURKA
expression as detected by real-time PCR (top row, red bars). Similarly,
knockdown (KD) of MED1 (green bars) or MED12 (yellow bars) reduced
expression of SNAI1 or AURKA. b, Knockdown of ncRNA-a3 or Mediator
subunits decreased TAL1 expression. Expression of TAL1 or control STIL after
knockdown of ncRNA-a3 (red bars), MED1 (green bars) or MED12 (yellow
bars) is shown. c, d, Knockdown of ncRNA-a7 (c) or ncRNA-a3 (d) reduces the
genomic occupancy of MED1, MED12 (top row) or RNAPII (bottom row) on
SNAI1, AURKA (c) or TAL1 (d) in A549 cells. e, f, Activating ncRNAs
specifically stimulate Mediator kinase activity towards histone H3.1 substrate
in vitro. Quantification of kinase assay after addition of ncRNA-a7 (e) or
ncRNA-a3 (f) is shown. Error bars represent6 s.e.m. (n5 3), P, 0.01 by two-
tailed Student’s t-test. The mean6 s.e.m. for all results represents three
independent experiments. *P, 0.05, **P, 0.01, ***P, 0.001 by two-tailed
Student’s t-test.
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To assess the association of endogenous ncRNA-a and Mediator,
the Flag–MED12 affinity-purified Mediator was fractionated by gel
filtration and column fractions were subjected to western blot analysis
and polymerase chain reaction with reverse transcription (RT–PCR)
to detect the associated ncRNA-a (Fig. 3c). Whereas the HEK293
nuclear extract contained similar levels of ncRNA-a1, ncRNA-a3,
HOTAIR andHOTTIP (HEK293 cells do not express ncRNA-a7; Sup-
plementary Fig. 3a), we could only detect ncRNA-a1 and ncRNA-a3
in association with the affinity-purified Mediator (Fig. 3c). Indeed,
ncRNA-a1 and ncRNA-a3 displayed a co-elution with components
of the Mediator complex on gel filtration, further supporting their
association with Mediator (Fig. 3c). Next, we performed RNA immu-
noprecipitation following ultraviolet crosslinking (UV-RIP) with anti-
MED12 antibodies or IgG, as control. Activating ncRNA-a1 and
ncRNA-a3 were significantly enriched in the MED12 UV-RIP,
whereas other abundant control messenger RNAs or non-coding
RNAs such as GAPDH, HOTAIR, HOTTIP and XIST were not
(Fig. 3d). Two mutations in MED12 proteins have been linked to
the development of the human genetic disorder Opitz–Kaveggia syn-
drome (also know as FG syndrome), causing physical anomalies and
developmental delays17,18 (Fig. 3e). Notably, whereas suchmutations in
MED12 donot affect its associationwith otherMediator subunits, they
significantly diminish its association with ncRNA-a1 and ncRNA-a3
as measured by UV-RIP (Fig. 3f, g).
We next askedwhether we could detect long-range chromatin loop-
ing between the ncRNA-a7 locus and its targets, SNAI1 and AURKA
and whether ncRNA-a7 and theMediator complex have a role in such
an association. We performed chromosome conformation capture
(3C) to assess the association of ncRNA-a7 with AURKA as well as
SNAI1. We also performed a similar analysis between ncRNA-a3 and
the TAL1 gene. We used anchoring points near the 39 untranslated
region of ncRNA-a7 or ncRNA-a3 tomeasure the extent of chromatin
looping between the ncRNA-a7 or ncRNA-a3 locus and their targets as
shown in Fig. 4a, d and Supplementary Fig. 3b, c. This analysis revealed
a strong association between the ncRNA-a7 locus and the region
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Figure 3 | Interaction of Mediator and activating ncRNAs is disrupted by
FG syndrome mutations of MED12. a, b, ncRNA-a associate with the
Mediator complex in vitro. RNA immune precipitation (RIP) was performed
using protein A dynabeads coupled with IgG, MED1 or MED12 antibodies.
Identical results were obtained in three independent experiments.
c, Purification ofMediator protein complex and associated RNAs. The purified
Flag–MED12 affinity elution was subjected to Superose 6 size-exclusion
chromatography and theMediator subunits were detected by western blot. The
Superose 6 fractions (14–38) are shown on top and molecular mass markers
(kilodaltons) are at the bottom. The RNAs in each fraction were extracted
followedbyRT–PCRusing specific primers.d, Ultraviolet crosslink followedby
RIP using HEK293T whole-cell lysates. The associated RNAs were analysed by
RT–qPCR with individual specific RNA primers. The mean6 s.e.m. are from
three independent experiments. ***P, 0.001 by two-tailed Student’s t-test.
e, Protein sequences of MED12 mutants causing FG syndrome. Part of the
protein sequence of MED12 exon 21 is shown (top tow). The mutated sites
indicate the G958E mutation (underlined) and the R961W mutation
(underlined). f, HEK293T cells were transfected with Flag–MED12 or mutant
constructs. After ultraviolet crosslinking, total cell extracts were
immunoprecipitated and analysed by western blotting. g, After UV-RIP of
wild-type and mutant MED12 samples shown in f, RT–qPCR was performed
using transcript-specific primers from the lncRNAs shown. The data are
representative of three independent experiments. The two-tailed Student’s
t-test indicated a P, 0.001 for ncRNA-a1 and ncRNA-a3, whereas there was
no significant difference for HOTAIR and HOTTIP.
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Moreover, ncRNA-a7 also displayed an interaction with regions near
the 59 end of theAURKA gene that extended into the body of the gene
(Fig. 4c, upper panel). There was no detectable association when a
control anchor was placed in the genomic region between ncRNA-a7
and AURKA (Fig. 4b, c).
Next we depleted the Mediator subunits MED1 or MED12 and
assessed their potential role in mediating the chromosomal looping
between ncRNA-a7, SNAI1 and AURKA. Depletion of either MED1
or MED12 completely abrogated the chromosomal looping between
ncRNA-a7 and SNAI1 (Fig. 4b, middle panel). A similar result was
obtained after depletion of MED1 or MED12 at the AURKA locus
(Fig. 4c, middle panel). Importantly, depletion of ncRNA-a7 had
a comparable effect, reducing the chromosomal looping between
ncRNA-a7 and both SNAI1 and AURKA loci (Fig. 4b, c, lower panels).
Because depletion of ncRNA-a7 using siRNAs resulted in a partial
decrease of ncRNA-a7 concentration (about 60% depletion, Sup-
plementary Fig. 1), the residual ncRNA-a7maybe sufficient topromote
smaller levels of DNA looping seen after ncRNA-a7 depletion.
We also performed a similar analysis measuring the extent of DNA
looping between ncRNA-a3 and that of the TAL1 locus. Similar to
results obtained with ncRNA-a7, we detected a specific and robust
DNA looping between ncRNA-a3 and TAL1 (Fig. 4e). Finally, deple-
tion of Mediator subunits MED1 and MED12 or ncRNA-a3 nearly
abolished the DNA looping between ncRNA-a3 and TAL1 (Fig. 4e,
middle and lower panels). Notably, Mediator and ncRNA-a asso-
ciation with their target genes extend beyond the transcription start
sites to include the more distal sites. This may reflect the engagement
of proximal regulatory elements in ncRNA-a andMediator chromatin
looping (Fig. 4b, e). These results suggest a mechanism of action for
ncRNA-a and Mediator that may involve additional chromatin
contacts beyond that which has been observed for distal regulatory
elements and transcriptional start sites.
We propose a new mechanism of action for a class of lncRNAs
termed ncRNA-activating (ncRNA-a) involved in long-range tran-
scriptional activation through their association with the Mediator
complex (Supplementary Fig. 4). It is noteworthy that suchMediator–
ncRNA-a-dependent chromatin loops extend beyond the transcrip-
tion start sites of the target promoters, which may reflect the inclusion
of promoter proximal regulatory elements in such associations. Future
studies could also assess whether such ncRNA-a–Mediator chro-
matin loops augment, or function exclusively of, Mediator–Cohesin
complexes23.
Recently, experiments in zebrafish uncovered a fundamental role
for lncRNAs in developmental control24. Moreover, recent reports
have linked a number of lncRNAs to human diseases such as cancer
and neurological disorders11,25–27. Importantly, our studies indicated
that Mediator complexes containing disease-causing mutant MED12
proteins corresponding to FG syndrome fail to associate with ncRNA-
a. These results underscore the significance of Mediator–ncRNA-a
association and suggest the loss of such Mediator–ncRNA-a interac-
tions as a possible contributing factor in such developmental disorders.
METHODS SUMMARY
Depletion experiments using siRNA/DNA transfection and ncRNA luciferase
assays. pGL3-TK-ncRNA-a and pGL3-TK-control constructs were generated as
described previously. On-TargetPlus siRNAs and non-targeting control siRNA
were purchased from Dharmacon. The modified siDNA oligonucleotides were
purchased from Integrated DNA Technologies. siRNA/DNA transfections were
50 kb50 kb
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Figure 4 | Mediator complex and ncRNA-a promote chromatin looping.
The schematic diagrams represent the genomic locus between the ncRNA-a7,
SNAI1 and AURKA loci (a), and the ncRNA-a3 and TAL1 loci (d). The top
arrows show the position of primers, the digestion sites are shown in the
middle, and the s1–s8, A–G or 1–8 fragments are presented below. The looping
events between ncRNAs and their targets were detected between ncRNA-a7
and SNAI1 (b), ncRNA-a7 andAURKA (c) and ncRNA-a3 and TAL1 (e) using
chromosome conformation capture (3C). Depletion of MED1 or MED12
abolished the loop interaction (b, c, e; middle panels). Knockdown of ncRNA-
a7 or ncRNA-a3 reduced the chromosomal looping events (b, c, e; lower
panels). The interaction frequency between the anchoring points and distal
fragments was determined by real-time PCR and normalized to BAC templates
and control anchors. Each error bar represents6 s.e.m. from three
independent experiments, P, 0.01 by two-tailed Student’s t-test.
Representative gel images of the 3C experiments for AURKA are presented in
Supplementary Fig. 3.
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performed with Lipofectamine RNAiMAX (Life Technologies) according to the
manufacturer’s instructions, using 50 nM siRNA/DNAs in a final volume of 2ml
of culture medium without antibiotics. Cells were collected 48–72 h after two
rounds of transfection.
Chromatin immunoprecipitation analysis was performed using 13 107 to
33107 A549 or MCF7 cells were collected for each independent immunopreci-
pitation. After chemically crosslinking, cells were fixed in 1% formaldehyde
13PBS with 10% serum for 15min at room temperature. After immunoprecipita-
tion, bound chromatin was eluted at 65 uC for 10min in 60ml fresh elution buffer
twice (TE, 1%SDS) and 80ml of elution bufferwas added to the final volume of 200
ml. Crosslinking samples were reversed overnight at 65 uC. After proteinase K
treatment (0.5mgml21), DNA was purified using a QIAquick PCR purification
kit (Qiagen).
Protein affinity purification and RNA immunoprecipitation. The affinity-
purified mediator complex and the GFP protein control were generated from
the Flag-taggedMED12 orGFPHEK293T stable cell lines. RNAprobes, internally
labelled with [a-32P]CTP, were transcribed using T7 or Sp6 RNA polymerase
(Riboprobe System, Promega). RNA immunoprecipitationswere performed using
Dynabeads Protein A (Invitrogen) according to the manufacturer’s recommen-
dations. Transient transfected HEK293T cells were UV-crosslinked at 254nm
(200mJ cm22) in 10 ml ice-cold PBS and collected by scraping. Cells were incu-
bated in lysis solution (0.1% SDS, 0.5% NP40, 0.5% sodium deoxycholate,
400Uml21 RNase inhibitor (Roche)), and protease inhibitor at 4 uC for 25min
with rotation, followed by DNase treatment (30U of DNase, 15min at 37 uC).
Full Methods and any associated references are available in the online version of
the paper.
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METHODS
siRNA/DNA transfection and ncRNA luciferase assays. pGL3-TK-ncRNA-a
and pGL3-TK-control constructs were generated as described previously. Firefly
luciferase constructs, pRL-CMV and a selectablemarker for puromycin resistance
were co-transfected in HEK293T cells. Transfected cells were grown in the pre-
sence of 2.5mgml21 puromycin (Sigma) for selection. Individual colonies were
isolated and screened for luciferase expression. Luciferase assays were performed
in 96-well white plates using Dual-Glo luciferase assay system (Promega) accord-
ing to the manufacturer’s protocol.
On-TargetPlus siRNAs and non-targeting control siRNAwere purchased from
Dharmacon. The modified siDNA oligonucleotides were purchased from
Integrated DNA Technologies. siRNA or siDNA transfections were performed
with Lipofectamine RNAiMAX (Life Technologies) according to the manufac-
turer’s instructions, using 50 nM siRNA/DNAs in a final volume of 2ml of culture
medium without antibiotics. Cells were collected 48–72 h after two rounds of
transfection.
Corresponding ncRNA-a HEK293T cell lines growing in 12-well dishes were
transfected with corresponding siRNA oligonucleotides, using Metafectene Pro
(Biontex Laboratories). Twenty-four hours after transfection, the cells were lysed
in 200ml passive lysis buffer (Promega), and firefly and Renilla luciferase activities
were measured on 30ml lysate using the Dual-Luciferase reporter assay kit
(Promega). Individual experiments were realized in triplicate, and the ratios pre-
sented are the averages of three independent experiments.
siRNA sequences. siControl1: ON-TARGET non-targeting siRNA 1 (D-001810-
01); siControl2: ON-TARGET Non-targeting siRNA 2 (D-001810-02); siGFP:
GFP Duplex I (P-002048-01); sincRNA-a3-1: 59-CUAUGGAAUUUAAGCCCA
AUU-39; sincRNA-a3-2: 59-GCAAGAUCACGGUGCGUCAUU-39; sincRNA-
a7-1: 59-CCGAUUUGAGAGAGUGAGAUU-39; sincRNA-a7-2: 59-GAAGGGA
ACCAGUGCUAAAUU-39; siMED12: 59-UCACUCAUCUCAUGUUAUAUU-
39; siNIPBL: 59-GGGAAUAUGAAGAGCGUGAUU-39; siCCNT1: 59-GAACAA
ACGUCCUGGUGAUUU-39; siCDK9: 59-UGACGUCCAUGUUCGAGUAUU-
39; siCEBPA: 59-ACAAGAACAGCAACGAGUAUU-39; siEP300: 59-GGACUA
CCCUAUCAAGUAAUU-39; siGTF2B: 59-ACAAUCAGACAGUCCUAUAUU-
39; siSMC1L: 59-CAUCAAAGCUCGUAACUUCUU-39.





C*C*A*C-39. Asterisks indicate nucleoside phosphorothioates.
shRNA infections. pLKO.1 lentiviral vector containing short hairpin RNAs
(shRNAs) or shRNA targeting GFP control was obtained from Open Biosys-
tems. The TRC shRNA constructs were purchased from Open Biosystems using
Lentiviral packaging system. Twenty-four hours after infection, selection with
2.5mgml21 puromycin was performed for 48 h.
shRNA list. shGFP: RHS4459; MED12 (TRCN0000018576): 59-CGGGT
ACTTCATACTTTGG-39; MED17 (TRCN0000019245): 59-CCGAGCTTGC
AGTTATCTATT-39; MED18 (TRCN0000053164): 59-GCCAGAAATGGG
AGACAAGAA-39; MED1 (TRCN0000019800): 59-GCCGAGTTCCTCTTA
TCCTAA-39; MED21 (TRCN0000013429): 59-CCATTGGAGTATTGCA
GCAAT-39; MED15 (TRCN0000018969): 59-GCTCAGAACCAACCATCAC-
39; MED16 (TRCN0000022139): 59-CGACATTGACAAGGTCATGAT-39;
MED23 (TRCN0000019196): 59-CGCAGTTTACACGCTTCCT-39; WDR5
(TRCN0000118050): 59-CCAACCTTATTGTCTCAGGAT-39.
Antibodies and recombinant proteins. Antibodies and recombinant proteins
used were: Pol II (SC-899, Santa Cruz), MED1 (A300-793A, Bethyl labs), MED12
(A300-774A,Bethyl labs), histoneH3Ser10p (05-598,Millipore), CDK8 (SC-1521,
Santa Cruz), CCNC (cyclin C, SC-1061, Santa Cruz), human rHistone H3.1
(M2503S, NEB), and human rCCNH (pka-364, Prospec protein specialists).
RNA purification, cDNA synthesis and quantitative PCR. Cells were collected
and re-suspended in TRIzol (Invitrogen) and RNA extracted according to the
manufacturer’s protocol. cDNA synthesis was done using random primers with
Fermentas RevertAid first-strand cDNA synthesis kit. Quantitative PCRwas done
using IQ SYBR green super-mixes and CFX96 Touch Real-Time PCR detection
system (Bio-rad). For all quantitative PCR reactionsGAPDHwasmeasured for an
internal control and used to normalize the data. qPCR primer sequences are listed
here: ncRNA-a1-qfor: 59-GCAAGCGGAGACTTGTCTTT-39; ncRNA-a1-qrev:
59-GGCTGGTCTTGAACTCCTGA-39; ncRNA-a3-qfor: 59-TTAAGCCCAAG
GAATGGAGA-39; ncRNA-a3-qrev: 59-AGCGGTGTGGAATAAACTGG-39;
ncRNA-a7-q1for: 59-ATCCTGGTGGAAAAGGCATC-39; ncRNA-a7-q1rev: 59-
GCCTGGGAAAAGCTACTTCA-39; ncRNA-a7-q2for: 59-CCGTTGGCTCCA
CAAACCT-39; ncRNA-a7-q2rev: 59-CAGTGACAGTAGCAGGCATCCT-39;
MED17-qfor: 59-CCCAGCGGATAGACTTCAGC-39; MED17-qrev: 59-ATTGT
TCCTCACTGAGTCCCA-39; MED18-qfor: 59-GGGCACCATTAACATGAT
GGA-39; MED18-qrev: 59-TGGTCAAGGAAAGTCTCAGGT-39; MED1-qfor:
59-CTGGAACGGCTCCATGCAA-39; MED1-qrev: 59-CTTCTCCATGACTTG
ACGCAC-39; MED21-qfor: 59-TTGCACGAACAGCAAAAGACA-39; MED21-
qrev: 59-TGCGCTTTGTATCTTCTCCAG-39; MED15-qfor: 59-ATGGACG
TTTCCGGGCAAG-39; MED15-qrev: 59-GCATCCTCGATTTGACTGACCA-
39; MED16-qfor: 59-TGCTGGACATGAACACACTG-39; MED16-qrev: 59-AGG
GAACCCTGGTTGGGTA-39; MED23-qfor: 59-GGGCCTTCAGACAGTTTTG
G-39; MED23-qrev: 59-AGCTGTGTTCTTTCCCACTCA-39; MED12-qfor: 59-
CTCCCGATGTTTACCCTCAG-39; MED12-qrev: 59-ATGCTCATCCCCAGA
GACAG-39; NIPBL-qfor: 59-CGGCCCGGATTATAGTCTCT-39; NIPBL-qrev:
59-TCAGGTGCCAGCTGTCATTA-39; CCNT1-qfor: 59-GCCAATCTGCTTC
AGGACA-39; CCNT1-qrev: 59-GGGAACTGTGTGAAGGACTGA-39; CDK9-
qfor: 59-ATACGAGAAGCTCGCCAAGA-39; CDK9-qrev: 59-CCTTCTCGT
TTTCCATCAGC-39; CEBPA-qfor: 59-CAGAGGGACCGGAGTTATGA-39;
CEBPA-qrev: 59-TTCACATTGCACAAGGCACT-39; EP300-qfor: 59-GGGAGG
ACAAACAGGATTGA-39; EP300-qrev: 59-CCAATCTGCTGTCCAGGATT-39;
GTF2B-qfor: 59-TTCCTGCTTTCGGTGTGTCT-39; GTF2B-qrev: 59-TGGATG
GTTTGGACATGTGA-39; SMC1L1-qfor: 59-TCGGACCATTTCAGAGGTTC-
39; SMC1L1-qrev: 59-GGTCTTTACCCGCAGGTTG-39; WDR5-qfor: 59-AAT
TCAGCCCGAATGGAGAGT-39; WDR5-qrev: 59-GGATATTCCCAGCTTGT
GACC-39; CSTF1-qfor: 59-ACAGAACCAAAGTGGGCTTGA-39; CSTF1-qrev:
59-ACACAGACTGAGGCTTGATTTC-39; AURKA-qfor: 59-TTCAGGACCTG
TTAAGGCTACA-39; AURKA-qrev: 59-ATTTGAAGGACACAAGACCCG-39;
TAL1-qfor: 59-CAGCCTAGTGGCTTGTCCTC-39; TAL1-qrev: 59-GGAGC
CTGAAATTGAATGGA-39; HOTAIR-qfor: 59-GGTAGAAAAAGCAACC
ACGAAGC-39; HOTAIR-qrev: 59-ACATAAACCTCTGTCTGTGAGTGCC-39;
HOTTIP-qfor: 59-CCTAAAGCCACGCTTCTTTG-39; HOTTIP-qrev: TGCAG
GCTGGAGATCCTACT-39; STIL-qfor: 59-CCCAACGCCAACTGGAGATTT-
39; STIL-qrev: 59-AGTCGGATGGTCTTCTCAGTC-39; SNAI1-qfor: 59-TCGG
AAGCCTAACTACAGCGA-39; SNAI1-qrev: 59-AGATGAGCATTGGCAGCG
AG-39; UBE2V1-qfor: 59-AAGCAAGAGCGACGCAAGAT-39; UBE2V1-qrev:
59-CGGAAATTGCGAGGGACTT-39.
Chromatin immunoprecipitation. Briefly, 13 107 to 33 107 A549 or MCF7
cells were collected for each independent immunoprecipitation. After chemically
crosslinking, cells were fixed in 1% formaldehyde, 13 PBS with 10% serum for
15min at room temperature. After quenching with 0.25M glycine, rinsing twice
with cold 13 PBS, cells were lysed for 15min in cold Chip buffer (150mMNaCl,
1% Triton X-100, 5mM EDTA; 10mM Tris-HCl, pH7.5, 0.5mM DTT) with
protease inhibitors on ice for 10min. DNA was sonicated to between 200- and
350-bp DNA fragments on a Diagenode Bioruptor according to manufacturer’s
protocol. The solubilized chromatin was cleared and diluted with lysis buffer
(without SDS to bring down SDS concentration to 0.1–0.15%). 1ml of the chro-
matin solution was incubated overnight with 2–6mg of antibody using protein A
Dyna Beads at 4 uC. The beads were washed twice withMixedMicelle wash buffer
(0.2% SDS, 1% Triton X-100, 5.2% w/v sucrose, 5mM EDTA, 20mM Tris-HCl,
pH8, 150mM NaCl), 2 times with high-salt buffer (1% Triton X-100, 1mM
EDTA, 50mM HEPES, pH8, 0.1% w/v deoxycholate, 500mM NaCl), 2 times
with LiCl buffer (250mM LiCl, 0.5% NP-40, 0.5% deoxycholate, 1mM EDTA,
10mM Tris-HCl, pH8), and one time with cold TE buffer (10mM Tris-HCl,
pH7.6, 1mM EDTA). Bound chromatin was eluted at 65 uC for 10min in 60ml
fresh elution buffer twice (TE, 1% SDS) and brought to 200ml. Crosslinking sam-
ples were reversed overnight at 65 uC. After proteinase K treatment (0.5mgml21),
DNA was purified using a QIAquick PCR purification kit (Qiagen). ChIP primers
sequences are listed here: AURKAChip-for: 59-CGAATCCTGCCCAATCTACC-
39; AURKAChip-rev: 59-GATGGCGAGAAAAGCAAGAG-39; ncRNAa7Chip-
for: 59-GGATAACCAAAAGCGTAGGAAA-39; ncRNAa7Chip-rev: 59-CGGTC
TCTAACAACAACAGCTC-39; CSTF1-Chip-for: 59-TCCATTTTTCCAGGAG
AGAGC-39; CSTF1-Chip-rev: 59-CCAGTCGTTTCTGTGGTTTTC-39; TAL1-
Chip-for: 59-TCCTTCCCCCTTTTCCTTAC-39; TAL1-Chip-rev: 59-TGAACGC
ACTCTCACAATCC-39; ncRNA-a3-Cfor: 59-ATGAGAGCCTCGGAAGTTGA-




Protein affinity purification and RNA immunoprecipitation. The affinity-
purified Mediator complex and the GFP protein control were generated from
the Flag-tagged MED12 or GFP HEK293T stable cell lines.
RNA probes, internally labelled with [a-32P]CTP, were transcribed using T7 or
Sp6 RNA polymerase (Riboprobe System, Promega).
RNA immunoprecipitations were performed using Dynabeads Protein A
(Invitrogen) according to manufacturer’s recommendations. 2mg antibody was
incubated with each sample, and the purified protein complex or the control
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protein together with labelled RNA probes were incubated with the beads at 4 uC.
The immunoprecipitated RNAs were extracted by TRIzol (Invitrogen) and
resolved on the 6% Novex TBE-Urea gels (Invitrogen).
For ultraviolet crosslinking experiments, the method is modified from that of
ref. 28. Transient transfected HEK293T cells were UV-crosslinked at 254nm
(200mJ cm22) in 10ml ice-cold PBS and collected by scraping. Cells were incu-
bated in lysis solution (0.1% SDS, 0.5% NP40, 0.5% sodium deoxycholate,
400Uml21 RNase Inhibitor (Roche)) and protease inhibitor at 4 uC for 25min
with rotation, followed by DNase treatment (30U of DNase, 15min at 37 uC).
In vitro transcription of ncRNA-a. In vitro transcription followed the protocol
provided by the Riboprobe in vitro transcription systems (Promega); the designed









TTTCCAGCGTTCTC-39. Uppercase letters inciate either the T7 or SP6 polymer-
ase binding site, whereas lowercase letters indicate specific sequences for each
ncRNA.
Kinase assays. Kinase reactions were carried out with 10–50ng of purified
Mediator protein complex and 500ng human histone H3.1 recombinant (New
England Biolabs) substrates in kinase buffer (25mM Tris pH8.0, 100 mM KCl,
100mMATP, 10mMMgCl2, 2mMDTT)with the addition of 2.5mCi [c-
32P]ATP
at 24 uC. Samples were resolved on a 4–12% SDS–polyacrylamide gel (Invitrogen)
followed by transfer to PVDF membrane (Millipore) and autoradiography.
Chromosome conformation capture (3C). 3C assays followed the protocol from
ref. 29, with minor modifications. A549 or MCF7 cells were filtered through a
70mm filter to obtain a single-cell preparation. 13 107 cells were then fixed in 1%
formaldehyde for 30min at room temperature, followed by 15min crosslinking.
The reaction was quenched with 0.25M glycine and cells were collected by cent-
rifugation at 240g at 4 uC. The pellet was re-suspended in 0.5ml cold lysis buffer
(10mM Tris-HCl, pH7.5; 10mM NaCl; 5mM MgCl2; 0.1mM EGTA) with
freshly added protease inhibitors (Roche) and was lysed on ice for 15min. Cells
were Dounce homogenized on ice with pestle B using 15–20 strokes. The nuclei
were collected by centrifugation at 500g for 10min at 4 uC and were re-suspended
in 0.5ml of 1.23 restriction enzyme buffer (NEB), including 0.3% SDS and were
incubated for 1 h at 37 uC while shaking at 1,200 r.p.m. Two per cent (final con-
centration) Triton X-100 was added to the nuclei and then the samples were
incubated for 1 h at 37 uC while shaking. 400U restriction enzyme was added to
the nuclei and the samples were incubated at 37 uC overnight while shaking. 10ml
of the samples were collected before and after the enzyme reaction to evaluate
digestion efficiency. The reaction was stopped by addition of 1.6% SDS (final
concentration) and incubation at 65 uC for 30min while shaking at 1,200 r.p.m.
The sample was then diluted 10-fold with 1.153 ligation buffer (NEB) with added
1%TritonX-100 andwas incubated for 1 h at 37 uCwhile shaking at 900 r.p.m. 100
U T4 DNA ligase (NEB) were added to the sample and the reaction was carried
at 16 uC for 4 h followed by 30min at room temperature. 300mg of Proteinase
K were added to the sample and the reaction was carried at 65 uC overnight for
de-crosslink. RNA was removed by adding 300mg of RNase and incubating the
sample for 1 h at 37 uC. DNA was purified by twice phenol-chloroform extraction
and ethanol precipitation. Purified DNA was then analysed by conventional or
quantitative PCR. As a control for ligation products the BAC clones were digested
with 10U of restriction enzyme overnight and then incubatedwith 10UT4DNA-
ligase at 16 uC overnight. The DNA was extracted by phenol-chloroform and
precipitated with ethanol. Purified DNA was then analysed by conventional or
quantitative PCR. For real-time PCR, the DCt method was applied for analysing
data, using the BAC clone Ct values as control. Ct values were normalized for each
primer pair by setting the Ct value of 100ng of BAC-clone control random ligation





GGAGAGGAG-39; Backg-Control- SNAI1-rev: 59-TCCTAAGTCCCCAGTC
TCCA-39; ncRNA-a7 anchor primer: 59-CTAGGTCAGGCCCAAAGAGA-39;
ncRNA-a7 anchor control: 59-ACAGAATAACCCATCCCTTTTCC-39; A7-
anchorDigTest-for: 59-GCTTAACCCAGTGCAAGCTC-39; A7-anchorDigTest-
rev: 59-AGTTTGGAGGCTGGGAATCT-39; AURKA-N5DigTest-for: 59-CCT
GATTCTCACCCTCTTGG-39; AURKA-N5DigTest-rev: 59-GAGGCCCCAT
TCCTTAACAT-39; SNAI1-N2DigTest-for: 59-GGGAAAATGAGAGCAAAC
TCC-39; SNAI1-N2DigTest-rev: 59-AAGGCCAATGTGACAGAGATG-39; A3-
DigEcoRI-for: 59-CACTTACAGGAACAGAGGACTCA-39; A3-DigEcoRI-rev:
59-CAACTTCTAGATCAGCGCCTTC-39; 3C AURKA-BglII-A: 59-GGGACAT
AAATGGGAGACTGG-39; 3C AURKA-BglII-B: 59-TGGGAGGAACTCTTC
ACCTCT-39; 3C AURKA-BglII-C: 59-TGGCTCTTTGGTCTTGTCTCT-39; 3C
AURKA-BglII-D: 59-GTTTGGGCCGTTTCTTATTG-39; 3C AURKA-BglII-E:
59-CAGACCTGATTCTCACCCTCTTG-39; 3C AURKA-BglII-F: 59-CACCAA
CTTTTCTTCTCCACCAA-39; 3C AURKA-BglII-G: 59-CCACAGGCACTACT
GTTACCAA-39; 3C BglII.E-R1: 59-CCAGGGAGGACACAGCATAA-39; 3C
BglII.E-R2: 59-TGGTGTCTGGGTTGAAGTAACA-39; 3C BglII.E-R3: 59-TC
GGCACCTGGTAAACTAGC-39; ncRNA-a3 anchor primer: 59-CAACTTCTA
GATCAGCGCCTTC-39; ncRNA-a3 anchor control: 59-GTCTCTTTCTTTGAT
TGGAGTGG-39; TAL1-1: 59-GGGAATGGCAGAAGACAGAA-39; TAL1-2: 59-
GTGTCGGGTTTGTTTTTACCTC-39; TAL1-3: 59-CTCCATTTTTGCCTCTG
TCTCT-39; TAL1-4: 59-ATCTTTTCCGTGTAGCTCTTCCT-39; TAL1-5: 59-
TGGGTTTGATTGCTCAGTACC-39; TAL1-6: 59-TCAATTTTGCCTGCCAT
ACA-39; TAL1-7: 59-TTAAAAGGGCAGGGAGTTAAAAG-39; TAL1-8: 59-
CAGATAGCCAGGAAGCAAGG-39; SNAI1-1: 59-GCTTTGGTCCTGAAC
TCCTG-39; SNAI1-2: 59-AACAAACTCACATTAATAAAATATCCAGA-39;
SNAI1-3: 59-CTACAGTCGTGTGCCACCAA-39; SNAI1-4: 59-ATTGGCAAGA
AGGGGAAAAT-39; SNAI1-5: 59-TCCAACATCCCAGACCTTTC-39; SNAI1-6:
59-GACCATGAGAAAGCCAGAGG-39; SNAI1-7: 59-AAGCTCCAGTGGCAT
GTGAT-39; SNAI1-8: 59-TGGAGTCCTGGTGTGTTCTG-39. BAC clone ID:
RP-11-664B18, RP-11-1067D15, RP11-742I1 (Empire Genomics).
28. Jeon, Y. & Lee, J. T. YY1 tethers Xist RNA to the inactive X nucleation center. Cell
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29. Hage`ge, H. et al. Quantitative analysis of chromosome conformation capture
assays (3C-qPCR). Nature Protocols 2, 1722–1733 (2007).
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